Hepatocellular Carcinoma Clinical Trials

549 recruitingLast updated: June 17, 2026

There are 549 actively recruiting hepatocellular carcinoma clinical trials across 49 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1. Top locations include Guangzhou, Guangdong, China, Beijing, Beijing Municipality, China, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Hepatocellular Carcinoma Trials at a Glance

549 actively recruiting trials for hepatocellular carcinoma are listed on ClinicalTrialsFinder across 6 cities in 49 countries. The largest study group is Phase 2 with 209 trials, with the heaviest enrollment activity in Guangzhou, Beijing, and Shanghai. Lead sponsors running hepatocellular carcinoma studies include Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University, and Zhongda Hospital.

Browse hepatocellular carcinoma trials by phase

Treatments under study

About Hepatocellular Carcinoma Clinical Trials

Looking for clinical trials for Hepatocellular Carcinoma? There are currently 305 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatocellular Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatocellular Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 549 trials

Recruiting
Phase 1Phase 2

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health30 enrolled21 locationsNCT07547553
Recruiting
Phase 3

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma
AstraZeneca1,220 enrolled220 locationsNCT06921785
Recruiting
Phase 4

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Lung Non-Small Cell Carcinoma+18 more
OHSU Knight Cancer Institute160 enrolled1 locationNCT07405086
Recruiting

A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

HCC - Hepatocellular CarcinomaCTTACE(Transcatheter Arterial Chemoembolization)
Zhongda Hospital121 enrolled1 locationNCT07351669
Recruiting
Phase 1

A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

Hepatocellular Carcinoma
M.D. Anderson Cancer Center60 enrolled1 locationNCT07116486
Recruiting
Phase 2

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma
Canadian Cancer Trials Group140 enrolled12 locationsNCT06880523
Recruiting

mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis

CirrhosisHepatocellular Carcinoma (HCC)Epigenomics+1 more
Central Hospital, Nancy, France400 enrolled1 locationNCT06778317
Recruiting
Phase 2

Y-90 Treatment Response Using Transarterial Radioembolization

Liver CancerHepatocellular CarcinomaPrimary Liver Cancer+3 more
Thomas Jefferson University30 enrolled1 locationNCT07145801
Recruiting
Phase 2

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.74 enrolled1 locationNCT06986785
Recruiting

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

Liver surgeryHepatocellular Carcinoma (HCC)Adjuvant Chemoradiotherapy+3 more
Second Affiliated Hospital, School of Medicine, Zhejiang University11,000 enrolled1 locationNCT07417800
Recruiting
Phase 1Phase 2

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

Hepatocellular CarcinomaMetastatic Liver CancerLiver Cancer, Adult+1 more
Eureka Therapeutics Inc.60 enrolled8 locationsNCT04864054
Recruiting
Phase 2

Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC

Hepatocellular Carcinoma (HCC)
Shunda Du32 enrolled1 locationNCT07639138
Recruiting
Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Not Applicable

A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC

Early Hepatocellular Carcinoma
University Health Network, Toronto218 enrolled2 locationsNCT07628751
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled5 locationsNCT07419841
Recruiting

Liver Cancer Registry Platform

CholangiocarcinomaHepatocellular Carcinoma (HCC)
iOMEDICO AG1,000 enrolled1 locationNCT04510740
Recruiting
Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Hepatocellular CarcinomaLocally Advanced MelanomaMetastatic Hepatocellular Carcinoma+7 more
National Cancer Institute (NCI)30 enrolled1 locationNCT06066138
Recruiting
Phase 1Phase 2

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma+4 more
Pfizer138 enrolled35 locationsNCT07227012
Recruiting

Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

Hepatocellular Carcinoma (HCC)
City of Hope Medical Center600 enrolled1 locationNCT07265271
Recruiting
Phase 2

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

Hepatocellular Carcinoma
University of Florida12 enrolled1 locationNCT05669339